Afinitor

Type: Product
Name: Afinitor
First reported 23 hours ago - Updated 23 hours ago - 1 reports

ONE WOMANS FIGHT WITH BREAST CANCER

for postmenopausal women with advanced HR+/HER2 negative breast cancer in combination with exemestane (a commonly used option) after failure of treatment with letrozole or anastrozole, offering another option for patients.“My diagnosis helped me realize ... [Published Montana News Association - 23 hours ago]
First reported Apr 11 2014 - Updated Apr 12 2014 - 1 reports

National Cancer Institute investigating trial outliers to resurrect 'failed' drugs

Last year the National Cancer Institute announced the launch of an initiative meant to examine failed clinical trials in search of "exceptional responders": patients who responded well to drugs that the bulk of the trial population didn't.Now, after sifting ... [Published FierceBiotech - Apr 11 2014]
First reported Apr 09 2014 - Updated Apr 10 2014 - 1 reports

The CementBloc Named Finalists in Three Categories for the 2014 DTC National

Advertising Awards04/09 13:33 CDT Advertising Awards NEW YORK, April 9, 2014NEW YORK, April 9, 2014 /PRNewswire/ -- The CementBloc, a leading healthwellness communications company headquartered in New York City, has been named a finalist in three ... [Published Finwin - Apr 09 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 1 reports

Cancer analysis tools circumvent biopsies

NEW YORK — For people with cancer or suspected cancer, the biopsy is a necessary evil — an uncomfortable and somewhat risky procedure to extract tissue for diagnosis or analysis.Lynn Lewis, a breast cancer patient in Brooklyn, has had her cancer analyzed ... [Published Boston Globe - Apr 08 2014]
First reported Apr 03 2014 - Updated Apr 03 2014 - 1 reports

Three New Personalized Medicines for Breast Cancer Excites Dr. Mai...

Active research in breast cancer is producing novel targeted drugs at a rapid pace. As the Cancer society continues research for breast cancer, several options have emerged. Of these options three drugs have been approved by the FDA for usage as treatment ... [Published PRWeb - Apr 03 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 1 reports

Bionomics announces encouraging results from Phase II renal cancer trial

Bionomics Limited, a biopharmaceutical company, has announced results from the Phase II DISRUPTOR-1 trial of BNC105 in patients with metastatic renal cancer. "The DISRUPTOR-1 trial has been the first of its kind in testing the combination of an mTOR inhibitor ... [Published Individual.com - Mar 31 2014]
First reported Mar 31 2014 - Updated Mar 31 2014 - 1 reports

Breast cancer drug therapy "set to become more dynamic"

The landscape for breast cancer therapies is set to become more dynamic, as newer targeted agents and drug combinations launch over the next few years, according to new research from Decision Resources. A US survey conducted for the study also finds that, ... [Published Pharma Times - Mar 31 2014]
First reported Mar 28 2014 - Updated Mar 28 2014 - 1 reports

Factors driving oncologists’ prescribing decisions for HER2-positive breast cancer patients

Efficacy, more than any other factors, drives oncologists’ prescribing of targeted therapies for breast cancer and, according to the majority of oncologists surveyed by Decision Resources, the escalating overall cost of drug treatment for breast cancer ... [Published Pharma Letter - Mar 28 2014]
First reported Mar 25 2014 - Updated Mar 25 2014 - 3 reports

AfinitorAromasin combo disappoints in breast cancer trial

A combination of Novartis' Afinitor and Pfizer's Aromasin failed to reach statistical significance in a trial’s secondary endpoint of overall survival. Eagerly-awaited results from ... ... [Published Big News Network - Mar 25 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 1 reports

Novartis: Afinitor plus exemestane extended OS, PFS in HR-positive/HER2-negative breast cancer

Novartis International recently reported secondary endpoint results of the phase 3 BOLERO-2 trial, which found that everolimus plus exemestane extended OS by 4.4 months compared to exemestane alone.Presented at the European Breast Cancer Conference in ... [Published Orthopedics Today - Mar 21 2014]
First reported Mar 20 2014 - Updated Mar 20 2014 - 1 reports

Data on Novartis' Afinitor

Novartis ( NVS ) announced additional results from a phase III trial, BOLERO-2 (Breast cancer trials of OraL EveROlimus-2) on cancer drug, Afinitor.The results from the trial (n=700) were presented at the 9th European Breast Cancer Conference in Scot ... [Published Yahoo! Canada - Mar 20 2014]
First reported Mar 20 2014 - Updated Mar 20 2014 - 4 reports

Novartis announces data from Phase III breast cancer trial

Novartis AG has announced data from secondary endpoint analysis of Phase III BOLERO-2, or Breast cancer trials of OraL EveROlimus-2, study of Afinitor in patients with HR+/HER2- advanced breast cancer. A median overall survival duration of 31 months was ... [Published Individual.com - Mar 20 2014]

Quotes

"The blockbuster business model that underpins big Pharma's success is now irreparably broken. The industry needs a new approach."
...amount of capital to support the clinical development of our three programs," commented Rexahn's Chief Executive Officer, Peter D Suzdak, Ph D "We are very excited about the progress of the Supinoxin™, RX-3117, and Archexin® clinical development programs, and we believe that 2014 will be a transformational year for Rexahn with clinical data expected from all three programs. I look forward to updating our shareholders on the upcoming milestones as appropriate and appreciate their support."
"We are delighted to be nominated for our work on behalf of Afinitor," says Elizabeth Elfenbein, Partner, Creative, at the Cementbloc. "These women living with ABC are amazing and deserve more. It's so rewarding to create a branded experience that gets into their skin and shows them that we understand them."
"BNC105 has the potential to change the way renal cancer is treated and the DISRUPTOR-1 trial has given us an insight on those patients who respond best to treatment. This is valuable information to incorporate in future clinical trial design and from the regulatory and reimbursement perspectives" Dr Iglesias added

More Content

All (63) | News (61) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (1)
sort by: Date | Relevance
ONE WOMANS FIGHT WITH BREAST CANCER [Published Montana News Association - 23 hours ago]
A Conversation With David I. Quinn, MBBS, PhD, ... [Published The ASCO Post - Apr 15 2014]
Don’t underestimate the potential of new products [Published pharmaphorum - Apr 14 2014]
Novartis overtakes Pfizer as top drug company [Published Crains Detroit Business - Apr 14 2014]
Bladder Cancer Patient With Rare Genetic Mutati... [Published The ASCO Post - Apr 12 2014]
National Cancer Institute investigating trial o... [Published FierceBiotech - Apr 11 2014]
Asia Pacific Solid Tumors Market 2013-2019 [Published Individual.com - Apr 11 2014]
Rexahn Pharmaceuticals : Reports Fourth Quarter... [Published 4 Traders - Apr 10 2014]
The CementBloc Named Finalists in Three Categor... [Published Finwin - Apr 09 2014]
Cancer analysis tools circumvent biopsies [Published Boston Globe - Apr 08 2014]
Cancer Analysis Tools Circumvent Biopsies [Published Columbus - Apr 08 2014]
Pfizer Inc's Palbociclib Delivers the Goods [Published Motley Fool Discussion Boards - Apr 07 2014]
Three New Personalized Medicines for Breast Can... [Published PRWeb - Apr 03 2014]
Everolimus benefited bladder cancer patient wit... [Published Orthopedics Today - Apr 01 2014]
Novartis announces good heart drug results [Published Medical Marketing And Media - Mar 31 2014]
Bionomics announces encouraging results from Ph... [Published Individual.com - Mar 31 2014]
Breast cancer drug therapy "set to become more ... [Published Pharma Times - Mar 31 2014]
Factors driving oncologists’ prescribing decisi... [Published Pharma Letter - Mar 28 2014]
Patent expiration, stagnant R&D spend seriously... [Published PharmaBiz - Mar 28 2014]
What is Nice? Drugs body Q [Published Telegraph - Mar 27 2014]
Fears thousands could be denied life-extending ... [Published Telegraph - Mar 27 2014]
Dear Pharmacist: Detoxify the body for better p... [Published Herald & Review - Mar 27 2014]
Report: Breast Cancer Treatment Will Become Mor... [Published P&T Community - Mar 26 2014]
Husband Seeks Compassionate Use Of Anti-PD-1 Dr... [Published Forbes.com - Mar 26 2014]
AfinitorAromasin combo disappoints in breast ca... [Published Big News Network - Mar 25 2014]
AfinitorAromasin combo disappoints in breast ca... [Published BioPortfolio - Mar 25 2014]
Afinitor/Aromasin combo disappoints in breast c... [Published Pharma Times - Mar 25 2014]
Exceptional Response Points to New Bladder Canc... [Published American Journal of Public Health - Mar 24 2014]
Rexahn provides updates on clinical development... [Published News-Medical.Net - Mar 24 2014]
Rexahn Pharmaceuticals Reports Fourth Quarter a... [Published BusinessWeek - Mar 24 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Here’s Why Novartis’ Japanese Unit Was Raided [Published Wall St. Cheat Sheet - Feb 23 2014]
Last month, the Japanese Health Ministry filed a complaint against Switzerland-based drugmaker Novartis AG’s ( NYSE:NVS ) Japan unit after the company used allegedly false data to advertise for its best-selling blood pressure drug, Diovan , the ...
1

Press Releases

sort by: Date | Relevance
Curis and Debiopharm Group(TM) Announce Initiat... [Published GlobeNewswire: Advertising News - Oct 22 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.